Analysts at Zacks Research assumed coverage on shares of Alaunos Therapeutics (NASDAQ:TCRT – Get Free Report) in a report released on Tuesday, Zacks reports. The firm set a “hold” rating on the stock.
Other research analysts also recently issued reports about the stock. TD Cowen began coverage on shares of Alaunos Therapeutics in a research report on Friday, November 13th. They issued a “buy” rating on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Alaunos Therapeutics in a research report on Friday, November 13th. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Alaunos Therapeutics has a consensus rating of “Hold”.
Get Our Latest Stock Report on Alaunos Therapeutics
Alaunos Therapeutics Stock Up 3.6%
Shares of Alaunos Therapeutics stock opened at $1.72 on Tuesday. The firm has a market capitalization of $7.24 million, a P/E ratio of -0.90 and a beta of -1.02. Alaunos Therapeutics has a 52 week low of $0.72 and a 52 week high of $4.50. The firm’s 50 day moving average is $1.65 and its two-hundred day moving average is $2.26.
Alaunos Therapeutics (NASDAQ:TCRT – Get Free Report) last released its quarterly earnings data on Monday, November 16th. The company reported ($0.31) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.05) by $1.74. As a group, research analysts expect that Alaunos Therapeutics will post -0.20 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Alaunos Therapeutics
An institutional investor recently bought a new stake in Alaunos Therapeutics stock. Integrated Wealth Concepts LLC bought a new position in shares of Alaunos Therapeutics, Inc. (NASDAQ:TCRT – Free Report) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 50,000 shares of the company’s stock, valued at approximately $44,000. Integrated Wealth Concepts LLC owned 1.51% of Alaunos Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). 27.72% of the stock is currently owned by institutional investors and hedge funds.
Alaunos Therapeutics Company Profile
Alaunos Therapeutics was a biotechnology company focused on developing engineered T-cell therapies for cancer. Its research centered on T-cell receptor (TCR) therapies designed to help a patient’s immune cells recognize and attack tumors. The company’s main program investigated genetically modified T cells targeting cancer-associated mutations, including mutations in the KRAS gene, in patients with solid tumors. Its approach used a library of TCRs intended to recognize different tumor mutations.
Further Reading
- Five stocks we like better than Alaunos Therapeutics
- Target Stock Is Up Over 70%—Has the Easy Money Already Been Made?
- Amazon’s Zoox Just Joined Uber—Could That Change the Robotaxi Threat?
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
Receive News & Ratings for Alaunos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alaunos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
